NASDAQ:CRIS - Curis Stock Price, Price Target & More

$0.5416 -0.02 (-3.56 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$0.5416
Today's Range$0.54 - $0.5740
52-Week Range$0.47 - $2.70
Volume796,181 shs
Average Volume2.07 million shs
Market Capitalization$93.32 million
P/E Ratio-1.50
Dividend YieldN/A
Beta1.28

About Curis (NASDAQ:CRIS)

Curis logoCuris, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

Receive CRIS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CRIS
CUSIP23126910
Phone617-503-6500

Debt

Debt-to-Equity Ratio1.49%
Current Ratio4.56%
Quick Ratio4.56%

Price-To-Earnings

Trailing P/E Ratio-1.50
Forward P/E Ratio-1.43
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.90 million
Price / Sales9.06
Cash FlowN/A
Price / CashN/A
Book Value$0.15 per share
Price / Book3.61

Profitability

EPS (Most Recent Fiscal Year)($0.36)
Net Income$-53,310,000.00
Net Margins-538.66%
Return on Equity-250.55%
Return on Assets-72.61%

Miscellaneous

Employees55
Outstanding Shares165,630,000

How to Become a New Pot Stock Millionaire

Curis (NASDAQ:CRIS) Frequently Asked Questions

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) issued its quarterly earnings results on Thursday, March, 8th. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.04. The biotechnology company had revenue of $3.26 million for the quarter, compared to analysts' expectations of $2.03 million. Curis had a negative net margin of 538.66% and a negative return on equity of 250.55%. During the same period in the previous year, the business earned ($0.08) earnings per share. View Curis' Earnings History.

When is Curis' next earnings date?

Curis is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Curis.

What price target have analysts set for CRIS?

2 analysts have issued 12 month price objectives for Curis' shares. Their predictions range from $7.00 to $7.00. On average, they anticipate Curis' share price to reach $7.00 in the next year. View Analyst Ratings for Curis.

What are Wall Street analysts saying about Curis stock?

Here are some recent quotes from research analysts about Curis stock:
  • 1. According to Zacks Investment Research, "Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. " (2/8/2018)
  • 2. Cowen Inc analysts commented, "In our view, recent underperformance of CRIS shares is not reflective of the continued." (5/5/2017)

Who are some of Curis' key competitors?

Who are Curis' key executives?

Curis' management team includes the folowing people:
  • Dr. Ali Fattaey, CEO, Pres & Director (Age 53)
  • Mr. James E. Dentzer, CFO, Chief Admin. Officer & Principal Accounting Officer (Age 51)
  • Dr. David Tuck, Sr. VP & Chief Medical Officer (Age 66)
  • Mr. Daniel R. Passeri M.Sc., MSc., J.D., Consultant (Age 57)
  • Mr. Mark W. Noel, VP of Technology Management & Intellectual Property (Age 59)

Has Curis been receiving favorable news coverage?

Media headlines about CRIS stock have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Curis earned a news sentiment score of 0.16 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.54 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Curis?

Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Curis' stock price today?

One share of CRIS stock can currently be purchased for approximately $0.5416.

How big of a company is Curis?

Curis has a market capitalization of $93.32 million and generates $9.90 million in revenue each year. The biotechnology company earns $-53,310,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Curis employs 55 workers across the globe.

How can I contact Curis?

Curis' mailing address is 4 MAGUIRE ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]


MarketBeat Community Rating for Curis (CRIS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  329 (Vote Outperform)
Underperform Votes:  255 (Vote Underperform)
Total Votes:  584
MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe CRIS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRIS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Curis (NASDAQ:CRIS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Curis in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 1,192.47%. The high price target for CRIS is $7.00 and the low price target for CRIS is $7.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$7.00$6.50$6.50
Price Target Upside: 1,192.47% upside345.86% upside314.01% upside314.01% upside

Curis (NASDAQ:CRIS) Consensus Price Target History

Price Target History for Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/23/2017GuggenheimInitiated CoverageBuy$7.00N/AView Rating Details
5/15/2017CowenReiterated RatingBuyN/AView Rating Details
3/11/2017FBR & CoSet Price TargetBuy$6.00LowView Rating Details
10/12/2016Royal Bank of CanadaSet Price TargetBuy$7.00N/AView Rating Details
9/7/2016Robert W. BairdReiterated RatingOutperform$7.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Curis (NASDAQ:CRIS) Earnings History and Estimates Chart

Earnings by Quarter for Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.31)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.07)($0.07)($0.07)
Q2 20181($0.08)($0.08)($0.08)
Q3 20181($0.08)($0.08)($0.08)
Q4 20181($0.08)($0.08)($0.08)

Curis (NASDAQ CRIS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($0.09)N/AView Earnings Details
3/8/2018Q4 2017($0.09)($0.05)$2.03 million$3.26 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.09)($0.11)$2.19 million$2.44 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.0930)($0.10)$2.08 million$2.10 millionViewListenView Earnings Details
5/4/2017Q1 17($0.0870)($0.11)$1.98 million$2.13 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.10)($0.08)$1.97 million$2.40 millionViewListenView Earnings Details
11/3/2016Q316($0.10)($0.21)$1.84 million$1.80 millionViewListenView Earnings Details
8/4/2016Q216($0.09)($0.09)$2.05 million$1.70 millionViewListenView Earnings Details
5/9/2016Q116($0.08)($0.07)$2.30 million$1.70 millionViewListenView Earnings Details
2/29/2016Q415($0.12)($0.10)$2.98 million$2.10 millionViewListenView Earnings Details
11/9/2015Q315($0.08)($0.04)$2.82 million$2.00 millionViewN/AView Earnings Details
8/6/2015Q215($0.06)($0.06)$3.50 million$2.10 millionViewN/AView Earnings Details
5/7/2015Q115($0.06)($0.07)$2.27 million$1.17 millionViewN/AView Earnings Details
2/24/2015Q4 14($0.07)($0.07)$2.69 million$2.00 millionViewN/AView Earnings Details
11/10/2014Q314($0.05)($0.06)$4.13 million$1.80 millionViewN/AView Earnings Details
8/7/2014Q214($0.06)($0.02)$3.46 million$4.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.07)($0.06)$1.88 million$1.30 millionViewN/AView Earnings Details
2/20/2014Q413($0.08)($0.05)$1.59 million$1.52 millionViewN/AView Earnings Details
11/5/2013Q313($0.01)($0.02)$6.44 million$7.20 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.05)($0.02)$4.43 million$5.40 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.05)($0.06)$3.86 million$0.90 millionViewN/AView Earnings Details
2/20/2013Q4 2012($0.08)($0.15)$2.07 million$1.69 millionViewN/AView Earnings Details
11/6/2012Q312($0.08)($0.04)$1.01 million$0.60 millionViewN/AView Earnings Details
8/2/2012($0.05)($0.04)ViewN/AView Earnings Details
5/8/2012$0.02$0.03ViewN/AView Earnings Details
2/8/2012Q4 2011$0.06$0.08ViewN/AView Earnings Details
10/27/2011($0.07)($0.05)ViewN/AView Earnings Details
7/28/2011($0.07)($0.06)ViewN/AView Earnings Details
4/28/2011Q1 2011($0.07)($0.09)ViewN/AView Earnings Details
2/10/2011Q4 2010($0.06)($0.07)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.03)($0.02)ViewN/AView Earnings Details
8/3/2010Q2 2010($0.04)($0.03)ViewN/AView Earnings Details
5/6/2010Q1 2010$0.05$0.06ViewN/AView Earnings Details
2/25/2010Q4 2009($0.05)($0.04)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.06)($0.06)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.07)($0.07)ViewN/AView Earnings Details
5/5/2009Q1 2009$0.01$0.02ViewN/AView Earnings Details
2/10/2009Q4 2008($0.03)($0.03)ViewN/AView Earnings Details
10/28/2008Q3 2008($0.07)ViewN/AView Earnings Details
7/30/2008Q2 2008($0.03)ViewN/AView Earnings Details
4/30/2008Q1 2008($0.05)ViewN/AView Earnings Details
2/14/2008Q4 2007$0.07ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Curis (NASDAQ:CRIS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Curis (NASDAQ CRIS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.34%
Institutional Ownership Percentage: 47.78%
Insider Trading History for Curis (NASDAQ:CRIS)
Institutional Ownership by Quarter for Curis (NASDAQ:CRIS)

Curis (NASDAQ CRIS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2017Marc RubinDirectorBuy25,000$0.98$24,500.0051,596View SEC Filing  
11/15/2017Ali Ph.D. FattaeyCEOBuy50,000$1.06$53,000.00115,890View SEC Filing  
5/5/2017James R McnabDirectorSell76,276$2.04$155,603.04879,688View SEC Filing  
5/2/2017James R McnabDirectorSell116,708$2.38$277,765.04View SEC Filing  
4/27/2017James R McnabDirectorSell146,694$2.61$382,871.34912,426View SEC Filing  
4/24/2017James R McnabDirectorSell110,322$2.59$285,733.981,357,147View SEC Filing  
9/7/2016Discovery Technologie AurigeneMajor ShareholderBuy10,208,333$2.40$24,499,999.2027,328,464View SEC Filing  
5/27/2016Martyn D GreenacreDirectorSell15,000$1.69$25,350.0040,183View SEC Filing  
5/26/2016Kenneth I KaitinDirectorSell15,000$1.76$26,400.0031,800View SEC Filing  
12/30/2015Daniel R. PasseriDirectorSell14,400$3.01$43,344.00198,898View SEC Filing  
12/29/2015Daniel R. PasseriDirectorSell11,200$2.91$32,592.00198,898View SEC Filing  
12/28/2015Daniel R. PasseriDirectorSell13,600$2.85$38,760.00198,898View SEC Filing  
12/23/2015Daniel R. PasseriDirectorSell48,900$2.78$135,942.00198,898View SEC Filing  
12/21/2015Daniel R. PasseriDirectorSell289,000$2.99$864,110.00198,898View SEC Filing  
8/27/2014Ali Ph.D. FattaeyCEOBuy62,890$1.60$100,624.00View SEC Filing  
12/11/2013Ali Ph.D. FattaeyCOOBuy3,000$2.52$7,560.003,000View SEC Filing  
11/12/2013Michael GrayCFOBuy10,000$2.86$28,600.00107,304View SEC Filing  
11/8/2013Kenneth PientaDirectorBuy20,000$2.95$59,000.0030,000View SEC Filing  
8/16/2013James McnabDirectorSell50,000$4.00$200,000.001,079,688View SEC Filing  
12/6/2012Daniel R PasseriCEOBuy25,000$3.03$75,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Curis (NASDAQ CRIS) News Headlines

Source:
DateHeadline
Curis, Inc. (CRIS) Expected to Announce Quarterly Sales of $2.30 MillionCuris, Inc. (CRIS) Expected to Announce Quarterly Sales of $2.30 Million
www.americanbankingnews.com - April 22 at 4:22 AM
Are Earnings Prospects Improving For Loss-Making Curis Inc’s (NASDAQ:CRIS)?Are Earnings Prospects Improving For Loss-Making Curis Inc’s (NASDAQ:CRIS)?
finance.yahoo.com - April 21 at 8:25 AM
-$0.08 Earnings Per Share Expected for Curis, Inc. (CRIS) This Quarter-$0.08 Earnings Per Share Expected for Curis, Inc. (CRIS) This Quarter
www.americanbankingnews.com - April 20 at 7:57 AM
Free Post Earnings Research Report: Curis’ Quarterly Revenue Jumped 38.10%Free Post Earnings Research Report: Curis’ Quarterly Revenue Jumped 38.10%
finance.yahoo.com - April 19 at 8:22 AM
Curis (CRIS) Downgraded to Sell at BidaskClubCuris (CRIS) Downgraded to Sell at BidaskClub
www.americanbankingnews.com - April 15 at 1:49 PM
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
www.prnewswire.com - April 6 at 7:33 AM
Zacks: Analysts Expect Curis, Inc. (CRIS) Will Post Quarterly Sales of $2.30 MillionZacks: Analysts Expect Curis, Inc. (CRIS) Will Post Quarterly Sales of $2.30 Million
www.americanbankingnews.com - April 5 at 4:20 AM
-$0.08 EPS Expected for Curis, Inc. (CRIS) This Quarter-$0.08 EPS Expected for Curis, Inc. (CRIS) This Quarter
www.americanbankingnews.com - April 3 at 9:18 AM
Investor Expectations to Drive Momentum within Atrion, Curis, Independence Contract Drilling, Utah Medical Products, FutureFuel, and Opiant Pharmaceuticals — Discovering Underlying Factors of InfluenceInvestor Expectations to Drive Momentum within Atrion, Curis, Independence Contract Drilling, Utah Medical Products, FutureFuel, and Opiant Pharmaceuticals — Discovering Underlying Factors of Influence
finance.yahoo.com - April 3 at 8:30 AM
Curis (CRIS) & Vical (VICL) Financial ComparisonCuris (CRIS) & Vical (VICL) Financial Comparison
www.americanbankingnews.com - April 2 at 5:22 AM
Curis (CRIS) Rating Lowered to Sell at Zacks Investment ResearchCuris (CRIS) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 29 at 8:30 PM
BRIEF-Curis Inc Says James Dentzer Became COO And CFO Of CoBRIEF-Curis Inc Says James Dentzer Became COO And CFO Of Co
www.reuters.com - March 22 at 5:31 PM
Curis: Time To Bet On A Courageous ChoiceCuris: Time To Bet On A Courageous Choice
seekingalpha.com - March 20 at 5:12 PM
 Brokerages Expect Curis, Inc. (CRIS) Will Post Quarterly Sales of $2.30 Million Brokerages Expect Curis, Inc. (CRIS) Will Post Quarterly Sales of $2.30 Million
www.americanbankingnews.com - March 19 at 7:56 AM
Head-To-Head Contrast: Kura Oncology (KURA) & Curis (CRIS)Head-To-Head Contrast: Kura Oncology (KURA) & Curis (CRIS)
www.americanbankingnews.com - March 17 at 8:07 AM
Curis, Inc. (CRIS) Expected to Announce Earnings of -$0.08 Per ShareCuris, Inc. (CRIS) Expected to Announce Earnings of -$0.08 Per Share
www.americanbankingnews.com - March 17 at 5:18 AM
Curis (CRIS) Presents At 38th Annual Cowen And Company Healthcare Conference - SlideshowCuris (CRIS) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 15 at 6:03 PM
What Are Analysts Saying About Curis Inc’s (NASDAQ:CRIS) Earnings Trend?What Are Analysts Saying About Curis Inc’s (NASDAQ:CRIS) Earnings Trend?
finance.yahoo.com - March 15 at 6:03 PM
Curis (CRIS) Announces  Earnings Results, Beats Estimates By $0.04 EPSCuris (CRIS) Announces Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - March 9 at 10:35 AM
Curis Reports Fourth Quarter and Year-End 2017 Financial ResultsCuris Reports Fourth Quarter and Year-End 2017 Financial Results
finance.yahoo.com - March 8 at 6:31 PM
Curis Reports Fourth Quarter and Year-End 2017 Financial Results - PR Newswire (press release)Curis Reports Fourth Quarter and Year-End 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - March 8 at 8:30 AM
Curis to Present at Cowen & Company 38th Annual Health Care Conference - PR Newswire (press release)Curis to Present at Cowen & Company 38th Annual Health Care Conference - PR Newswire (press release)
www.prnewswire.com - March 5 at 8:28 AM
Curis to Present at Cowen & Company 38th Annual Health Care ConferenceCuris to Present at Cowen & Company 38th Annual Health Care Conference
finance.yahoo.com - March 5 at 8:27 AM
Curis, Inc. (CRIS) Sees Significant Growth in Short InterestCuris, Inc. (CRIS) Sees Significant Growth in Short Interest
www.americanbankingnews.com - March 3 at 3:26 AM
Curis, Inc. (CRIS) Expected to Announce Quarterly Sales of $2.03 MillionCuris, Inc. (CRIS) Expected to Announce Quarterly Sales of $2.03 Million
www.americanbankingnews.com - March 2 at 2:24 PM
Baird Financial Group Inc. Decreases Stake in Curis, Inc. (CRIS)Baird Financial Group Inc. Decreases Stake in Curis, Inc. (CRIS)
www.americanbankingnews.com - March 2 at 4:42 AM
Curis to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018 - PR Newswire (press release)Curis to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018 - PR Newswire (press release)
www.prnewswire.com - March 1 at 8:20 AM
Curis to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018Curis to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018
finance.yahoo.com - March 1 at 8:20 AM
Curis, Inc. (CRIS) Receives Consensus Recommendation of "Hold" from AnalystsCuris, Inc. (CRIS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 28 at 3:32 AM
Zacks: Brokerages Anticipate Curis, Inc. (CRIS) Will Post Earnings of -$0.09 Per ShareZacks: Brokerages Anticipate Curis, Inc. (CRIS) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - February 28 at 3:12 AM
Curis (CRIS) to Release Earnings on WednesdayCuris (CRIS) to Release Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:40 AM
Brokers Offer Predictions for Curis, Inc.s FY2022 Earnings (CRIS)Brokers Offer Predictions for Curis, Inc.'s FY2022 Earnings (CRIS)
www.americanbankingnews.com - February 22 at 4:34 PM
Curis (CRIS) Upgraded at Zacks Investment ResearchCuris (CRIS) Upgraded at Zacks Investment Research
www.americanbankingnews.com - February 11 at 5:12 PM
Capstone Turbine Corporation (CPST) and Seadrill Ltd (SDRL) Among Hedge Funds’ Favorite Penny StocksCapstone Turbine Corporation (CPST) and Seadrill Ltd (SDRL) Among Hedge Funds’ Favorite Penny Stocks
finance.yahoo.com - February 8 at 8:15 AM
Curis, Inc. (CRIS) Given Average Recommendation of "Hold" by AnalystsCuris, Inc. (CRIS) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 3 at 3:26 AM
Short Interest in Curis, Inc. (CRIS) Expands By 101.8%Short Interest in Curis, Inc. (CRIS) Expands By 101.8%
www.americanbankingnews.com - January 28 at 1:26 AM
Curis, Inc. (CRIS) Expected to Post Earnings of -$0.09 Per ShareCuris, Inc. (CRIS) Expected to Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - January 25 at 1:29 PM
Curis (CRIS) Reports Initiation of Phase 1 Trial of CA-4948 - StreetInsider.comCuris (CRIS) Reports Initiation of Phase 1 Trial of CA-4948 - StreetInsider.com
www.streetinsider.com - January 18 at 10:46 AM
Curis (CRIS) Reports Initiation of Phase 1 Trial of CA-4948Curis (CRIS) Reports Initiation of Phase 1 Trial of CA-4948
www.streetinsider.com - January 17 at 9:45 AM
Curis Begins Phase 1 Trial Of CA-4948 In Patients With Lymphomas - Quick FactsCuris Begins Phase 1 Trial Of CA-4948 In Patients With Lymphomas - Quick Facts
www.nasdaq.com - January 17 at 9:45 AM
Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kinase in Patients with LymphomaCuris Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kinase in Patients with Lymphoma
finance.yahoo.com - January 17 at 9:45 AM
Zacks: Analysts Anticipate Curis, Inc. (CRIS) Will Announce Quarterly Sales of $2.03 MillionZacks: Analysts Anticipate Curis, Inc. (CRIS) Will Announce Quarterly Sales of $2.03 Million
www.americanbankingnews.com - January 10 at 5:00 PM
 Brokerages Anticipate Curis, Inc. (CRIS) to Announce -$0.09 Earnings Per Share Brokerages Anticipate Curis, Inc. (CRIS) to Announce -$0.09 Earnings Per Share
www.americanbankingnews.com - January 8 at 9:36 AM
Curis, Inc. (CRIS) Expected to Post Quarterly Sales of $2.03 MillionCuris, Inc. (CRIS) Expected to Post Quarterly Sales of $2.03 Million
www.americanbankingnews.com - December 25 at 10:32 PM
ETFs with exposure to Curis, Inc. : December 25, 2017ETFs with exposure to Curis, Inc. : December 25, 2017
finance.yahoo.com - December 25 at 6:42 PM
Want To Invest In Curis Inc (NASDAQ:CRIS)? Here’s How It Performed LatelyWant To Invest In Curis Inc (NASDAQ:CRIS)? Here’s How It Performed Lately
finance.yahoo.com - December 21 at 5:01 PM
Curis (CRIS) vs. Cellular Dynamics International (ICEL) Financial SurveyCuris (CRIS) vs. Cellular Dynamics International (ICEL) Financial Survey
www.americanbankingnews.com - December 16 at 5:16 AM
Curis, Inc. (CRIS) Receives Consensus Recommendation of "Hold" from BrokeragesCuris, Inc. (CRIS) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 15 at 3:32 AM
ETFs with exposure to Curis, Inc. : December 12, 2017ETFs with exposure to Curis, Inc. : December 12, 2017
finance.yahoo.com - December 12 at 5:24 PM
-$0.09 EPS Expected for Curis, Inc. (CRIS) This Quarter-$0.09 EPS Expected for Curis, Inc. (CRIS) This Quarter
www.americanbankingnews.com - December 5 at 7:12 AM

SEC Filings

Curis (NASDAQ:CRIS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Curis (NASDAQ:CRIS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Curis (NASDAQ CRIS) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.